The Effect of Factor Xa/Phospholipid Infusion on the Acute Phase Response in Baboons

Summary

Disseminated intravascular coagulation (DIC) is a frequent complication of septicemia or tissue injury and may be accompanied by elevations of interleukin-6, a mediator of the acute phase response. It is not known whether thrombin or fibrin deposition may directly induce an acute phase response. To study this, we employed a baboon model of in vivo thrombin generation, induced by the administration of purified bovine Factor Xa and phospholipid vesicles. Two Xa/phospholipid dosages were used, a low dosage (2 animals) leading to a rapid 49% decrease in fibrinogen and a high dosage (two injections at 5h interval; 3 animals) leading to complete fibrinogen depletion. Thereafter, fibrinogen levels increased in both treatment groups, reached a maximum of 2.52 ± 0.23 g/1 (mean ± SE, n = 5; p <0.01 with respect to basal levels) at day 2, and returned to normal by day seven. In five control (injection of 0.15% NaCl) baboons no significant changes of fibrinogen were observed (maximal values: 1.88 ± 0.12 g/1). Serum concentrations of C-reactive protein, an acute phase protein, increased from 3.7 ± 0.4 mg/1 to a maximum of 33.0 ± 7.3 at day one, which was five-fold higher (p <0.01) than in control animals at day one (6.2 ± 0.5 mg/1). Transient increases were observed within 6 h for interleukin-6 from basal values of 6.2 ± 1.7 ng/1 to peak plasma levels of 42.9 ±21.4 ng/1, a value threefold higher (p = 0.07) than in control animals (14.8 ± 4.0 ng/1).

The preliminary results of this observational study suggest that factor Xa/phospholipid infusion is followed by an acute phase response, leading after one day to significant increases of fibrinogen and of C-reactive protein.

• References

• 1 Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocapro-ic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med 1986; 105: 873-877
• 2 Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Cancer 1992; 70: 656-658
• 3 Levi M, ten Cate H, van der PollT, van Deventer SJH. Pathogenesis of intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
• 4 Levi M, ten Cate H, Bauer KA, van der PollT, Edgington TS, Büller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
• 5 Wada H, Tanigawa M, Wakita Y, Nakase T, Minamikawa K, Kaneko T, Ohiwa M, Kageyama S, Kobayashi T, Noguchi T, Deguchi K, Shirakawa S. Increased plasma level of interleukin-6 in disseminated intravascular coagulation. Blood Coagul Fibrinol 1993; 04: 583-590
• 6 Calandra T, Gérain J, Heumann D, Baumgartner JD, Glauser MP. and the Swiss-Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin 6 in patients with septic shock: evolution during sepsis, prognostic value and interplay with other cytokine. Am J Med 1991; 91: 23-29
• 7 Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human. IL-6 as a marker of severity. Ann Surg 1992; 215: 356-362
• 8 Mestries JC, Kruithof EKO, Gascon MP, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytkine Netw 1994; 05: 275-281
• 9 Van der PollT, Levi M, Hack CE, ten Cate H, Van Deventer SJH, Eerenberg AJM, De Groot ER, Jansen J, Gallati H, Büller HR, ten Cate JW, Aarden LA. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-1259
• 10 Sower LE, Froelich CJ, Carney DH, Fenton JW, 2nd, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 1995; 155: 895-901
• 11 Stankova J, Rola-Pleszczynski M, D’Orleans-Juste P. Endothelin 1 and thrombin synergistically stimulate IL-6 mRNA expression and protein production in human umbilical vein endothelial cells. Cardiovasc Pharmacol 1995; 26 (Suppl. 03) S505-S507
• 12 Robson SC, Shepherd EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-lβ, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-326
• 13 Mandl J, Csala M, Lerant I, Banhegyi G, Biro J, Machovich R, Falus A. Enhancement of interleukin-6 production by fibrinogen degradation product D in human peripheral monocytes and perfused murine liver. Scand J Immunol 1995; 42: 175-178
• 14 Giles AR, Nesheim ME, Herring SW, Hoogendoom H, Stump DC, Helde-brant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 1990; 63: 476-481
• 15 Podor TJ, Hirsh J, Gelehrter TD, Zeheb R, Torry D, Guigoz Y, Sierra F, Gauldie J. Type 1 plasminogen activator inhibitor is not an acute phase reactant in rats. Lack of IL-6-and hepatocyte-dependent synthesis. J Immunol 1993; 150: 225-235
• 16 Qi J, Kreutzer DL. Fibrin activation of vascular endothelial cells. Induction of IL-8 expression. J Immunol 1995; 155: 867-876